Krogerus advises Bioretec on its rights offering

Krogerus advised Bioretec on its rights offering of approximately EUR 12.9 million. DNB Carnegie Investment Bank AB, Finland Branch acted as the sole global coordinator in the rights offering. The offering was carried out under the exemption document regime (Annex IX of the EU Prospectus Regulation) made available by the EU Listing Act.

In connection with the offering, the Finnish Financial Supervisory Authority granted the largest shareholder of Bioretec a permanent exemption from the obligation to launch a mandatory public takeover bid. 

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec's shares are listed on Nasdaq First North Growth Market Finland.

The Krogerus team was led by Partner Tom Fagernäs. He was primarily assisted by Counsel Anna Sahrakorpi, Senior Associates Olli Silvennoinen and Kalle Lipsanen and Associates Roosa Järvi, Eemeli Kastikainen, and Helmi Räsänen (all Capital Markets and Public M&A).